



Saamya Biotech (India) Limited

Reg. Off.: 104-106, Lumbini Enclave, Opp. NIMS, Panjagutta, Hyderabad-500 082. Ph. No. 040-2339 3099 Fax No. 040-2339 7099
 web: www.saamyabiotech.com
 CIN : L24239AP2002PLC039449

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2015

PART - I		UNAUDITED					(In Rupees)
SI. No.	Particulars	QUARTER ENDED			HALF YEAR ENDED		AUDITED
		30-09-2015	30-06-2015	30-09-2014	30-09-2015	30-09-2014	YEAR ENDED 31-03-2015
1	Income from operations						
	a) Net Sales / Income from Operations (net of excise duty)	7,67,07,236	6,73,14,705	-	14,40,21,942	-	28,76,83,992
	b) Other Operating Income	-	-	-	-	-	-
	Total income from operations (net)	7,67,07,236	6,73,14,705	-	14,40,21,942	-	28,76,83,992
2	Expenses						
	a) Purchase of Traded Goods	7,65,15,860	6,71,46,850	-	14,36,62,710	-	28,38,10,010
	b) Employee benefit expenses	2,49,000	2,49,000	2,46,000	4,98,000	4,92,000	9,91,000
	c) Other Expenses	4,04,463	15,984	42,804	4,20,447	1,26,482	5,11,096
	d) Depreciation	22,94,525	22,94,525	5,72,609	45,89,050	11,45,218	99,61,006
	Total expenses	7,94,63,848	6,97,06,359	8,61,413	14,91,70,207	17,63,700	29,52,73,112
3	Profit from operations before other income, interest & Exceptional items (1-2)	(27,56,612)	(23,91,654)	(8,61,413)	(51,48,266)	(17,63,700)	(75,89,120)
4	Other Income	9,76,900	-	-	9,76,900	-	2,67,635
5	Profit from operations before Interest & Exceptional items (3+4)	(17,79,712)	(23,91,654)	(8,61,413)	(41,71,366)	(17,63,700)	(73,21,485)
6	Finance costs (Interest & Bank charges)	2,762	16,547	10,243	19,309	67,262	6,347
7	Profit from operations after finance cost but before Exceptional Items (5-6)	(17,82,474)	(24,08,200)	(8,71,656)	(41,90,674)	(18,30,962)	(73,27,832)
8	Exceptional Items	-	-	-	-	-	-
9	Profit (+)/Loss (-) from Ordinary Activities before tax (7+8)	(17,82,474)	(24,08,200)	(8,71,656)	(41,90,674)	(18,30,962)	(73,27,832)
10	Tax Expenses	-	-	-	-	-	(5,39,937)
11	Net Profit (+) / Loss (-) from Ordinary Activities after tax (9-10)	(17,82,474)	(24,08,200)	(8,71,656)	(41,90,674)	(18,30,962)	(67,87,895)
12	Extraordinary items (net of tax expenses)	-	-	-	-	-	-
13	Net profit(+)/Loss (-) for the period (11-12)	(17,82,474)	(24,08,200)	(8,71,656)	(41,90,674)	(18,30,962)	(67,87,895)
14	Paid up Equity Share Capital (Face value of Rs. 10/- each)	24,88,25,000	24,88,25,000	24,88,25,000	24,88,25,000	24,88,25,000	24,88,25,000
15	Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	3,81,39,971	3,81,39,971	4,49,27,866	3,81,39,971	4,49,27,866	4,49,27,866
16	EPS (of Rs. 10 each) (not annualized)						
	a) Basic	(0.07)	(0.10)	(0.04)	(0.17)	(0.07)	(0.27)
	b) Diluted	(0.07)	(0.10)	(0.04)	(0.17)	(0.07)	(0.27)
PART - II							
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	Number of shares	1,60,07,900	1,60,07,900	1,60,07,900	1,60,07,900	1,60,07,900	1,60,07,900
	Percentage of shareholding	64.33	64.33	64.33	64.33	64.33	64.33
2	Promoters and promoter group Shareholding						
a)	Pledged/Encumbered						
	1. Number of Shares	-	-	-	-	-	-
	2. Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	3. Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b)	Non- Encumbered						
	1. Number of Shares	88,74,600	88,74,600	88,74,600	88,74,600	88,74,600	88,74,600
	2. Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100	100
	3. Percentage of shares (as a % of the total share capital of the company)	35.67	35.67	35.67	35.67	35.67	35.67
B	INVESTORS COMPLAINTS FOR THE QUARTER ENDED 30-9-2015			OPENING BALANCE	ADDITIONS	DISPOSED	CLOSING BALANCE
	COMPLAINTS RECEIVED FROM INVESTORS			NIL	NIL	NIL	NIL



S. Manjunathan Reddy



Saamya Biotech (India) Limited

Reg. Off.: 104-106, Lumbini Enclave, Opp. NIMS, Panjagutta, Hyderabad-500 082. Ph. No. 040-2339 3099 Fax No. 040-2339 7099
 web: www.saamyabiotech.com
 CIN : L24239AP2002PLC039449

STATEMENT OF ASSETS AND LIABILITIES

		(In Rupees)	
	PARTICULARS	AS AT 30-09-2015 (UNAUDITED)	AS AT 31-03-2015 (AUDITED)
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
	a) Share Capital	24,88,25,000	24,88,25,000
	b) Reserves & Surplus	3,39,49,297	3,81,39,971
	Sub-total - Shareholders funds	28,27,74,297	28,69,64,971
2	Share application money pending allotment	-	-
3	Non-Current liabilities		
	a) Long-term borrowings	3,24,00,656	3,63,00,656
	b) Deferred tax liabilities (net)		-
	d) Other long-term liabilities		-
	e) Long-term provisions		-
	Sub-total - Non-current liabilities	3,24,00,656	3,63,00,656
4	Current liabilities		
	a) Short-term borrowings		-
	b) Trade payables	46,80,08,188	39,83,19,217
	c) Other current liabilities	7,86,976	7,69,014
	d) Short-term provisions	89,08,219	69,75,182
	Sub-total - Current liabilities	47,77,03,383	40,60,63,413
	TOTAL - EQUITY AND LIABILITIES	79,28,78,336	72,93,29,040
B	ASSETS		
1	Non-current assets		
	a) Fixed Assets	28,24,70,770	28,90,56,080
	b) Non-current investments		-
	c) Deferred tax assets (net)	2,23,768	2,23,768
	d) Long-term loans and advances	15,98,506	15,98,506
	e) Other non-current assets	1,18,841	1,18,841
	Sub-total - Non-current assets	28,44,11,885	29,09,97,195
2	Current assets		
	a) Current investments		-
	b) Inventories		-
	c) Trade receivables	50,18,15,114	43,17,19,001
	d) Cash & Bank Balances	1,24,564	1,61,723
	e) Short-term loans and advances	65,26,773	64,51,121
	f) Other current assets		-
	Sub-total - Current assets	50,84,66,451	43,83,31,845
	TOTAL - ASSETS	79,28,78,336	72,93,29,040

Note:

- 1) The above unaudited results were reviewed by the audit committee and subsequent approval by the Board of Directors at their respective meeting held on 13-11-2015. The results are subject to Limited Review by the Auditors of the Company.
- 2) Previous period/year's figures have been regrouped and rearranged wherever necessary.
- 3) The company operates in single segment only, hence segment reporting is not applicable.

Place : Hyderabad
 Date : 13-11-2015



For and on behalf of Board of Directors

Dr. Y. Manivardhan Reddy

Dr. Y. Manivardhan Reddy
 DIN: 01368438
 Managing Director & CEO



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470

Fax : (91-40) 2339 2474

E-mail : pmurali.co@gmail.com
info@pmurali.com


Website : www.pmurali.com


To
The Board of Directors
SAAMYA BIOTECH (INDIA) LIMITED
Hyderabad

Limited Review Report for the quarter ended 30th September, 2015

1. We have reviewed the accompanying statement of unaudited financial results of M/s. SAAMYA BIOTECH (INDIA) LIMITED for the quarter ended 30th September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants


Partner



Place: Hyderabad
Date: 13th November, 2015